abstract |
Provided are medicaments and methods for preventing or treating pre-core mutant hepatitis B virus disease, and lamivudine-resistant, pre-core mutant hepatitis B virus disease, in human patients comprising administering to a patient in need thereof a therapeutically effective amount of 2-amino-9-[2-[bis(2,2,2-trifluoroethoxy)phosphonylmethoxy]ethyl]-6-(4-methoxy-phenylthio) purine .1 |